Current evidence does not support use of expanded or basic carrier screening panels, CFTR targeted analyses, CFTR sequencing (including panels using at minimum the ACMG-100 variant set), CFTR intron 9 polyT/TG analysis, or SMN1 targeted variant analysis for indications other than those explicitly listed in this policy (primarily preconception or pregnancy-related indications). These investigational or not‑supported statements reflect that coverage is limited to the specific clinical situations described in the criteria sets (e.g., members who are considering pregnancy or are currently pregnant and, where applicable, specified family history or partner carrier conditions).

When a test is billed outside the policy’s stated indications, claims may be considered noncompliant with the medical necessity criteria. Providers should ensure the indication meets the test‑specific criteria before ordering or billing these assays.

Each specific test section in this policy includes an investigational or not‑supported statement clarifying that the listed test is considered not supported for carrier screening "for all other indications." For example, basic and expanded panels, CFTR analyses, SMN1 testing, FMR1 repeat analysis, hemoglobinopathy testing, and Ashkenazi panels all state that coverage is limited to the pregnancy/preconception contexts and the family‑history or partner‑carrier conditions described in the criteria.

When separate CPT codes (e.g., FMR1 81243) are billed with a panel code (e.g., 81443), the member must still meet the specific test criteria described in the policy (for instance, Fragile X criteria when 81243 is billed).

Investigational language in the policy has been clarified to state that "current evidence does not support…" for specified uses outside the listed indications. Sequencing and deletion/duplication tests (for example CFTR sequencing using the ACMG‑100 variant set) and intronic analyses (CFTR polyT/TG) are explicitly limited to the circumstances named in the criteria (e.g., pregnancy/preconception, partner known carrier, or presence of R117H for polyT/TG testing).

Policy updates aligned CFTR sequencing variant thresholds with the 2023 ACMG technical statement (changing the referenced minimum tested variant set to 100) and clarified investigational language for sequencing/deletion/duplication testing.

Coverage of services described in this clinical policy is subject to all terms, conditions, exclusions, and limitations of the member’s specific coverage documents and applicable state and federal requirements. The policy is a guide to medical necessity and does not itself guarantee payment; where plan coverage documents or law take precedence, those provisions govern.

Providers should verify benefits and prior authorization requirements with the member’s coverage documents before ordering testing.

The tests listed in this policy are not supported when used for indications outside those explicitly specified (for example, testing performed for purposes other than preconception or pregnancy screening, or without the required family‑history or partner criteria). Each test’s criteria specify the allowed clinical contexts; use outside those contexts is considered not supported by current evidence.

Providers should document the pregnancy/planning status and any required family or partner information specified by the test section (e.g., close relative with a known pathogenic variant) to support medical necessity.

Routine or population‑wide use of the targeted or sequencing carrier tests listed in this policy (for example, routine sequencing or deletion/duplication testing performed outside the specified pregnancy/planning and family‑history or partner‑carrier criteria) is not supported by current evidence. Basic panels are limited to no more than 14 genes and must include at minimum CFTR and SMN1 to meet the basic panel criteria.

ACMG guidance cited in the policy also discourages offering lower‑tier panels without Tier 3 testing and does not recommend routine offering of very broad panels for all patients.

During recent updates, certain clinical criteria were removed or relocated to align the policy with current professional guidance (for example, moving general targeted carrier screening criteria to a general genetic testing policy). Investigational language was updated and clarified to better reflect guideline‑based limits on indications and to remove items inconsistent with current recommendations.

Where changes affect coding or clinical thresholds (for example the CFTR variant count update to the ACMG‑100 reference), the policy text and supporting notes were revised to maintain consistency with cited professional society statements.

This clinical policy is provided as a guide to medical necessity and coverage determinations and does not itself constitute a contract, guarantee of payment, or medical advice. Specific prior authorization requirements, coverage determinations, and benefit limits are governed by the member’s coverage documents and applicable law.

Providers must follow the member’s evidence of coverage, certificate of coverage, and plan prior authorization processes when submitting claims for genetic carrier testing.

For coverage of CFTR or SMN1 targeted variant analysis, the policy requires documentation that the member (or reproductive partner) is considering pregnancy or is currently pregnant and that a close relative has a known pathogenic or likely pathogenic variant in the respective gene. Close relatives include first‑, second‑, and third‑degree relatives on the same side of the family; documentation of the related relative and prior molecular testing reports, when available, should be provided.

When a familial pathogenic variant is known, targeted testing directed at that variant is the appropriate covered approach; broader testing may not be supported unless the policy’s sequencing criteria are met.

SMN1 and CFTR targeted variant analyses require that the member or reproductive partner be considering pregnancy or currently pregnant and that a close relative has a known pathogenic or likely pathogenic variant in the respective gene. The policy emphasizes review of family history and prior molecular reports where available before ordering carrier testing.

If prior testing reports for affected relatives are unavailable, the policy notes situations where sequencing or deletion/duplication analysis (for example SMN1 sequencing/deletion‑duplication) may be the appropriate next step, particularly when the reproductive partner is a known carrier.

Top‑level eligibility requirements captured across the test sections consistently require the member (or reproductive partner) to be considering pregnancy or currently pregnant for coverage of carrier screening. Additional test‑specific eligibility nodes require family history or partner carrier status for targeted analyses (for example SMN1 targeted, HBA/HBA2/HBB targeted, DMD targeted), while sequencing/deletion/duplication criteria include partner carrier status or pregnancy/planning context as qualifying conditions.

Providers should refer to the specific test criteria in the policy to determine required documentation for eligibility (e.g., degree of relative, diagnosis in a family member, or partner carrier result).

For CFTR targeted variant analysis coverage, the member or reproductive partner must be considering pregnancy or currently pregnant and a close relative must have a known pathogenic or likely pathogenic CFTR variant. Documentation of the familial variant and relationship is required to support medical necessity.

If a familial variant is established in an affected relative, targeted methods that assess that specific variant are appropriate; broader sequencing is only covered under the policy’s sequencing criteria.

For SMN1 targeted variant analysis, the member or reproductive partner must be considering pregnancy or currently pregnant and a close relative must have a known pathogenic or likely pathogenic SMN1 variant for coverage. If the reproductive partner is a known carrier, SMN1 sequencing and/or deletion/duplication (with SMN2 analysis) may be covered under the expanded SMN1 sequencing criteria.

ACMG and ACOG guidance referenced in the policy support offering SMA screening to all women who are considering pregnancy or are currently pregnant and recommend reviewing affected family member testing before carrier testing.

Hemoglobinopathy targeted variant analysis requires pregnancy/planning status and a close relative with a known pathogenic or likely pathogenic HBA1, HBA2, or HBB variant for coverage. If the reproductive partner is known to be a carrier via hematologic or genetic testing, sequencing and/or deletion/duplication testing of HBA/HBB may be the more appropriate covered test.

ACOG recommends universal hemoglobinopathy screening in pregnancy; providers should document pregnancy status and any relevant partner or family testing when ordering molecular hemoglobinopathy analyses.

Supplemental eligibility nodes reference professional guidance: ACMG recommends partner follow‑up screening when a pathogenic or likely pathogenic variant is identified in one partner, and ACOG recommends offering carrier screening for CFTR and SMN1 to all women considering pregnancy or currently pregnant. Providers should follow these guidance statements when sequencing partner testing workflows.

Documentation supporting partner follow‑up and the decision to pursue targeted versus broader testing should be included in the medical record.

Supplemental eligibility considerations include ACOG recommendations to review prior molecular testing reports of affected family members (for example in cystic fibrosis and SMA) before testing. If familial testing is available, ensure the familial pathogenic variant is included in the assay or perform targeted testing for that variant.

Where prior reports are not available, the policy describes scenarios where sequencing or deletion/duplication testing may be indicated.

Additional supplemental eligibility notes reiterate society guidance for conditions such as Fragile X, SMA, and DMD: review family history and prior molecular reports when available, and consider full sequencing/CNV analysis when familial variants are unknown (for example DMD guidance from EMQN advising combined CNV and sequencing for ~99% sensitivity).

These guidance‑based supplemental nodes support the policy’s requirement to document family history and prior testing when applicable.

Use of the listed carrier screening tests for clinical indications other than those explicitly specified in this policy (that is, indications not related to preconception or pregnancy, or lacking the required family‑history or partner criteria) is considered not covered. The policy’s not‑covered language applies to targeted analyses, sequencing/deletion‑duplication testing, and panel testing when used outside the described contexts.

Providers should confirm that testing is being ordered for a covered indication per the policy before billing or submitting claims.

ACMG guidance cited in the policy discourages offering lower‑tier (Tier 1 or Tier 2) screening without Tier 3 and does not recommend routine offering of Tier 4 panels. The policy reflects these recommendations by specifying panel composition and by limiting routine or population‑wide use of broad panels outside the pregnancy/preconception contexts.

Basic panels must include core genes (CFTR, SMN1) and be limited to no more than 14 genes to meet the policy’s basic panel criteria.

Some tests or uses are labeled investigational or not supported where current evidence does not support their use outside the specified indications. The policy clarifies sequencing/deletion/duplication testing boundaries (for example, excluding fetal hemoglobin testing via circulating fetal DNA) and updated CFTR sequencing criteria to reference the ACMG‑100 variant recommendation.

When tests are considered investigational for an indication, coverage is not provided unless otherwise specified in plan documents.

The document segments available in this update do not list additional explicit exclusions beyond the test‑specific not‑supported statements; the policy’s not‑covered and investigational sections identify that tests are not supported outside the enumerated pregnancy/preconception and family/partner criteria.

For a complete list of exclusions or investigational items, providers should consult the full policy and the member’s coverage documents.

Carrier screening identifies asymptomatic individuals who carry pathogenic variants for autosomal recessive or X‑linked single‑gene disorders to assess reproductive risk. Professional societies recommend offering carrier screening prior to or early in pregnancy and strongly advise pre‑test and post‑test genetic counseling to support informed decision‑making and address preferences for secondary or incidental findings.

Documentation of counseling, informed consent, and discussion of partner testing should be included in the medical record when ordering carrier screening.